Experience evolves into evidence in the new MEN1 guidelines
Nearly a quarter of a century has passed since the publication of the first clinical practice guideline on multiple endocrine neoplasia type 1 (MEN1) in 2001, which followed the identification of the MEN1 gene.1,2 Together with a 2012 update, those guidelines accompanied the implementation of MEN1 genetic screening programmes worldwide.3 Thus began the crucial work of identifying genetically not only MEN1-affected patients but also pre-symptomatic MEN1 variant carriers at an ever-younger age. The data gathered over this period have shown us the nature of MEN1: that it is one of the most challenging hereditary cancer syndromes in medicine.
